HindustanTimes Sun,13 Jul 2014

Biocon, Bristol ink global deal

HT Correspondent, Hindustan Times  Mumbai, November 16, 2012
First Published: 23:23 IST(16/11/2012) | Last Updated: 23:26 IST(16/11/2012)

Biocon, India's largest biotechnology company by revenue, announced on Friday that it has signed an agreement with Bristol-Myers Squibb, which  opens up its oral insulin IN-105 to a worldwide market through a commercial arrangement powered by the multinational's wide reach. Financial terms of the deal were not disclosed.


Under the agreement, Bristol-Myers Squibb will have the right to exercise an option to obtain an exclusive worldwide licence to the programme. It will, however, conduct the clinical trials of the new drug candidate according to a pre-agreed development programme up to the completion of Phase II.

"This agreement is one huge step closer to realising the dream of bringing oral insulin to market," said Kiran-Mazumdar Shaw, MD and chairman, Biocon.

Biocon, which has been looking to partner the drug for nearly two years, said it would receive a licence fee as well as milestone payments and royalties based on sales of the drug outside India, but will retain India rights.

"If Bristol-Myers Squibb exercises the option to licence IN -105 following the successful completion of Phase II trial, it will assume full responsibility for the development programme, including all development and commercialisation activities outside India," said Biocon.

Currently, there are no insulin tablets available.

Earlier this year, Pfizer scrapped a deal to sell injectable insulin products made by Biocon.

more from Business

Doubling of tax on debt mutual funds to hit retirees

On Thursday, finance minister Arun Jaitley gave investors and the mutual fund industry a jolt by increasing the long-term capital gains tax on debt mutual funds to 20% from 10%. The definition of long-term has also been changed to 36 months for non-equity MFs from 12 months.
Most Popular
Copyright © 2014 HT Media Limited. All Rights Reserved